Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) EBIT Margin: 2024-2025

Historic EBIT Margin for Prime Medicine (PRME) over the last 2 years, with Sep 2025 value amounting to -4,405.96%.

  • Prime Medicine's EBIT Margin rose 2154237.00% to -4,405.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -3,412.48%, marking a year-over-year change of. This contributed to the annual value of -6,787.36% for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's EBIT Margin is -4,405.96%, which was up 7.96% from -4,787.17% recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's EBIT Margin ranged from a high of -2,025.74% in Q4 2024 and a low of -25,948.33% during Q3 2024.
  • In the last 2 years, Prime Medicine's EBIT Margin had a median value of -4,596.57% in 2025 and averaged -8,158.34%.
  • Data for Prime Medicine's EBIT Margin shows a peak YoY skyrocketed of 2,154,237bps (in 2025) over the last 5 years.
  • Over the past 2 years, Prime Medicine's EBIT Margin (Quarterly) stood at -2,025.74% in 2024, then spiked by 2,154,237bps to -4,405.96% in 2025.
  • Its last three reported values are -4,405.96% in Q3 2025, -4,787.17% for Q2 2025, and -3,603.30% during Q1 2025.